This is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT exons 11+17/18 mutations, and are without KIT exon 9, 13, or 14 mutations. Upon disease progression as determined by an independent radiologic review, participants randomized to sunitinib will be given the option to either crossover to receive ripretinib 150 mg QD or discontinue sunitinib.



Eligible Ages
Over 18 Years
Eligible Genders
Accepts Healthy Volunteers

Inclusion Criteria

  1. Male or female ≥18 years of age. 2. Histologic diagnosis of GIST with co-occurring KIT exons 11+17/18 mutations confirmed by ctDNA sample. 3. Participants must have advanced GIST and radiologic progression on imatinib treatment. 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤2 at screening. 5. Female participants of childbearing potential must have a negative pregnancy test at screening and prior to the first dose of study drug. 6. Participants of reproductive potential must agree to follow contraception requirements. 7. Participants must have at least 1 measurable lesion according to mRECIST v1.1 within 21 days prior to the first dose of study drug. 8. Adequate organ function and bone marrow reserve based on laboratory assessments performed at screening. 9. Resolution of all toxicities from prior therapy to Grade ≤1 (or participant baseline) within 1 week prior to the first dose of study drug.

Exclusion Criteria

  1. History of KIT exon 9 mutation or detection of KIT exon 9, 13, or 14 mutations in a ctDNA sample. 2. Has known active central nervous system metastases. 3. New York Heart Association Class II-IV heart disease, myocardial infarction within 6 months of Cycle 1 Day 1, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension, or congestive heart failure. 4. Use of strong or moderate inhibitors or inducers of cytochrome P450 (CYP) 3A prior to the first dose of study drug, and consumption of grapefruit or grapefruit juice within 14 days prior to the first dose of study drug. 5. Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug. 6. Known human immunodeficiency virus or hepatitis C infection only if the participant is taking medications that are excluded per protocol, acute or chronic hepatitis B, or acute or chronic hepatitis C infection. 7. Gastrointestinal abnormalities including, but not limited to: 1. inability to take oral medication 2. malabsorption syndromes 3. requirement for intravenous alimentation 8. Any active bleeding excluding hemorrhoidal or gum bleeding.

Study Design

Phase 3
Study Type
Intervention Model
Parallel Assignment
Primary Purpose
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
150 mg QD of ripretinib (3×50 mg tablets) will be dosed continuously in repeated 42-day cycles.
  • Drug: Ripretinib
    50 mg tablets
    Other names:
    • QINLOCK, DCC-2618
Active Comparator
50 mg QD of sunitinib (4×12.5 mg capsules) will be dosed in 42-day cycles. Sunitinib will be given continuously for 4 weeks with a 2-week break.
  • Drug: Sunitinib
    12.5 mg tablets
    Other names:
    • Sutent

Recruiting Locations

Boston Medical Center
Boston, Massachusetts 02118

More Details

Deciphera Pharmaceuticals LLC

Study Contact

Clinical Team


Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.